Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Group 1 - Astellas Pharma Inc. (ALPMY) is outperforming the Medical sector with a year-to-date return of 4.2%, while the sector has returned an average of -3.1% [4] - The Zacks Consensus Estimate for Astellas Pharma's full-year earnings has increased by 25.6% in the past quarter, indicating improved analyst sentiment [4] - Astellas Pharma belongs to the Medical - Drugs industry, which has an average loss of 3.9% this year, further highlighting its relative strength [6] Group 2 - The Medical group ranks 3 within the Zacks Sector Rank, which includes 16 different groups [2] - Astellas Pharma has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the stock [3] - AngioDynamics, another stock in the Medical sector, has a year-to-date return of 4.8% and a Zacks Rank of 1 (Strong Buy) [5]